MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
1.820
-0.070
-3.70%
After Hours: 1.820 0 0.00% 18:37 02/23 EST
OPEN
1.850
PREV CLOSE
1.890
HIGH
2.040
LOW
1.800
VOLUME
1.67M
TURNOVER
0
52 WEEK HIGH
23.53
52 WEEK LOW
0.3333
MARKET CAP
178.98M
P/E (TTM)
-0.5951
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at FGEN last week (0212-0216)?
Weekly Report · 6d ago
Sell Rating on FibroGen Amid Skepticism Over Clinical Outcomes and Drug Efficacy
TipRanks · 02/14 03:45
Weekly Report: what happened at FGEN last week (0205-0209)?
Weekly Report · 02/12 09:08
12 Health Care Stocks Moving In Wednesday's Intraday Session
ThermoGenesis Holdings (NASDAQ:THMO) stock moved upwards by 39.0% to $0.86 during Wednesday's regular session. Femasys shares increased by 21.51% and PepGen stock rose 13.77% during the same time period. Losers include CytoMed Therapeutics and Cingulate.
Benzinga · 02/07 17:31
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise
FibroGen, Inc. Shares have gained 148% in the last 30 days. The company's price-to-sales ratio of 1.2x is lower than the industry median. FibroGen's revenue growth has been slower than most other companies in the biotech industry. Its forecast growth of 5.0% for the next year is significantly lower than its peers.
Simply Wall St · 02/05 13:05
Weekly Report: what happened at FGEN last week (0129-0202)?
Weekly Report · 02/05 09:09
KOPN, CAMP and FGEN among mid-day movers
Seeking Alpha · 02/02 17:31
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Intelligent Bio Solutions (NASDAQ:INBS) shares rose 108.5% to $5.03 during Friday's regular session. Atara Biotherapeutics stock increased by 51.8% and Universe Pharmaceuticals shares rose 26.51%. Losers Cingulate stock decreased by 52.1% and GRI Bio shares fell 25.12%.
Benzinga · 02/02 17:31
More
About FGEN
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of therapeutics. It applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes. It also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Its Roxadustat is approved in China, Europe and Japan for the treatment of anemia in CKD.

Webull offers FibroGen Inc stock information, including NASDAQ: FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.